Abstract |
Approximately 10% of patients with glioblastoma survive more than 2 years after diagnosis. Distinguishing these patients from those who died within 2 years of diagnosis is clinically significant. We studied the MIB-1 labeling index (LI) and DNA topoisomerase II alpha LI of glioblastomas from 34 patients who lived for more than 2 years after diagnosis and of glioblastomas from 34 age- and sex-matched control patients who died within 2 years of diagnosis. The means of MIB-1 and topoisomerase II alpha LIs of the group with a better outcome were lower. With 35 as the cutoff point for the MIB-1 LI and 26 as the cutoff point for the topoisomerase II alpha LI, both MIB-1 and topoisomerase II alpha LIs were related significantly to survival. Our study showed that both MIB-1 and topoisomerase II alpha could help predict long-term survival of patients with glioblastomas. Multivariate analyses revealed that MIB-1 was a better prognostic marker than topoisomerase II alpha.
|
Authors | Donald Ming-Tak Ho, Chih-Yi Hsu, Ling-Tan Ting, Hung Chiang |
Journal | American journal of clinical pathology
(Am J Clin Pathol)
Vol. 119
Issue 5
Pg. 715-22
(May 2003)
ISSN: 0002-9173 [Print] England |
PMID | 12760291
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Neoplasm
- DNA-Binding Proteins
- Ki-67 Antigen
- DNA Topoisomerases, Type II
|
Topics |
- Adolescent
- Adult
- Antigens, Neoplasm
- Brain Neoplasms
(diagnosis, metabolism)
- Child
- Child, Preschool
- DNA Topoisomerases, Type II
(analysis)
- DNA-Binding Proteins
- Female
- Glioblastoma
(diagnosis, metabolism)
- Humans
- Immunohistochemistry
- Ki-67 Antigen
(analysis)
- Male
- Middle Aged
- Multivariate Analysis
- Prognosis
- Survivors
|